CompletedPhase 4NCT00284193

Combination Therapy of Low Doses of rFVIIa and FEIBA for Severe Hemophilia A Patients With an Inhibitor to Factor VIII

Studying Severe hemophilia A

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Sheba Medical Center
Principal Investigator: Uri Martinowitz, MD
Sheba Medical Center
Intervention: rFVIIa-FEIBA therapy for hemophilia A inhibitors(drug)
Enrollment: 5 target
Eligibility: 16-65 years · MALE
Timeline: 2005 – 2009

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00284193 on ClinicalTrials.gov

Other trials for Severe hemophilia A

Additional recruiting or active studies for the same condition.

ENROLLING BY INVITATIONNANCT06816953
Cartilage Biomarkers and HEAD-US Score in Severe Hemophilia A Patients Receiving FVIII Prophylaxis
Chulalongkorn University
RECRUITINGPHASE3NCT06142552
Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein
Jiangsu Gensciences lnc.
ACTIVE NOT RECRUITINGPHASE3NCT06224907
Phase 3 Study for Efficacy and Safety Outcomes Data in Japanese Patients With Severe Hemophilia A
BioMarin Pharmaceutical
RECRUITINGNCT05981274
A Study on the Bone-health Effectiveness of Applying Recombinant Factor VIII Fc (rFVIIIFc) to Patients With Hemophilia A (Prototype A)
Tri-Service General Hospital
ENROLLING BY INVITATIONNCT05768386
A Long-Term Follow-Up Study in Severe Hemophilia A Subjects Who Received BMN 270 in a Prior BioMarin Clinical Trial (270-401)
BioMarin Pharmaceutical
RECRUITINGPHASE4NCT04690322
POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement Therapies
University of Texas Southwestern Medical Center

See all trials for Severe hemophilia A →

← Back to all trials